This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lupu, C. Articles by Lupu, F. Search for Related Content PubMed PubMed Citation Articles by Lupu, C. Articles by Lupu, F. Related Collections Anticoagulant mechanisms Endothelium/vascular type/nitric oxide

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2251-2262.)
© 1999 American Heart Association, Inc.

Thrombosis

Cellular Effects of Heparin on the Production and Release of Tissue Factor Pathway Inhibitor in Human Endothelial Cells in Culture

Cristina Lupu; Emma Poulsen; Sylvie Roquefeuil; Andrew D. Westmuckett; Vijay V. Kakkar; Florea Lupu

From the Vascular Biology Laboratory, Weston Centre for Experimental Research, Thrombosis Research Institute, London, United Kingdom.

Correspondence to Dr Cristina Lupu, Thrombosis Research Institute, Emmanuel Kaye Bldg, Manresa Road, Chelsea, London SW3 6 LR, UK. E-mail clupu{at}tri-london.ac.uk

Abstract—Tissue factor pathway inhibitor (TFPI), the major downregulator of procoagulant activity of the tissue factor–factor VIIa complex (TF · FVIIa), is synthesized and constitutively secreted by endothelial cells (ECs). Here we describe the in vitro effects of heparin on the cellular localization, gene expression, and release of TFPI in human ECs in culture. Both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH; Fragmin) time-dependently induced a significant enhanced secretion of TFPI, paralleled by a redistribution and increase of TFPI on the cell surface and a decrease of intracellular TFPI. Immunogold electron microscopy showed the presence of clusters of TFPI, both on the plasmalemma proper and within cell-surface opened caveolae/enlarged caveolar profiles. Activation of FX by TF · FVIIa on ECs treated with endotoxin was inhibited by both heparins but to a higher extent by LMWH. Inhibition of protein synthesis by cycloheximide did not reduce the release of TFPI induced by heparin. Long-term incubation (48 hours) resulted in a time-dependent enhanced production of TFPI. After the first 4 to 8 hours, depletion of intracellular TFPI was observed, more significantly with UFH. Northern blot analysis of TFPI mRNA also showed a decrease of the 1.4-kb transcript after 4 hours of incubation with UFH, followed by recovery and an increase over the control level after 24 hours. Incubation of ECs with phorbol ester (PMA) significantly enhanced the secretion of TFPI and increased its activity on the cell surface, probably by preventing invagination of caveolae. Heparin-stimulated release of TFPI decreased significantly in the presence of PMA to a level that was 2.4 times lower than the expected additive value for PMA and UFH separately. Pretreatment of ECs with PMA suppressed a subsequent response to heparin. Altogether, our results suggest that the heparin-induced release of TFPI might involve a more specific mechanism(s) than the previously hypothesized simple displacement of TFPI from the cell surface glycocalyx. We assume that the increased secretion and redistribution of cellular TFPI induced by heparins in ECs in culture can play an important role in the modulation of the anticoagulant properties of the endothelium.

Key Words: tissue factor pathway inhibitor • human endothelial cells • unfractionated heparin • low-molecular-weight heparin • caveolae

This article has been cited by other articles:

				P. E.R. Ellery, K. Hardy, R. Oostryck, and M. J. Adams Further Insight Into the Heparin-Releasable and Glycosylphosphatidylinositol-Lipid-- Anchored Forms of Tissue Factor Pathway Inhibitor Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 267 - 278. [Abstract] [PDF]

				J. T.B. Crawley and D. A. Lane The Haemostatic Role of Tissue Factor Pathway Inhibitor Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 233 - 242. [Abstract] [Full Text] [PDF]

				C. I. Oie, R. Olsen, B. Smedsrod, and J.-B. Hansen Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G520 - G528. [Abstract] [Full Text] [PDF]

				C. Lupu, A. D. Westmuckett, G. Peer, L. Ivanciu, H. Zhu, F. B. Taylor Jr., and F. Lupu Tissue Factor-Dependent Coagulation Is Preferentially Up-Regulated within Arterial Branching Areas in a Baboon Model of Escherichia coli Sepsis Am. J. Pathol., October 1, 2005; 167(4): 1161 - 1172. [Abstract] [Full Text] [PDF]

				C. Lupu, X. Hu, and F. Lupu Caveolin-1 Enhances Tissue Factor Pathway Inhibitor Exposure and Function on the Cell Surface J. Biol. Chem., June 10, 2005; 280(23): 22308 - 22317. [Abstract] [Full Text] [PDF]

				J. Zhang, O. Piro, L. Lu, and G. J. Broze Jr Glycosyl Phosphatidylinositol Anchorage of Tissue Factor Pathway Inhibitor Circulation, August 5, 2003; 108(5): 623 - 627. [Abstract] [Full Text] [PDF]

				B. Naumnik, J. Borawski, and M. Mysliwiec Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study Nephrol. Dial. Transplant., July 1, 2003; 18(7): 1376 - 1382. [Abstract] [Full Text] [PDF]

				H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]

				I. Ott, V. Malcouvier, A. Schomig, and F.-J. Neumann Proteolysis of Tissue Factor Pathway Inhibitor-1 by Thrombolysis in Acute Myocardial Infarction Circulation, January 22, 2002; 105(3): 279 - 281. [Abstract] [Full Text] [PDF]

				A. Perez-Ruiz, R. Montes, P. Carrasco, and E. Rocha Effects of a Low Molecular Weight Heparin, Bemiparin, and Unfractionated Heparin on Hemostatic Properties of Endothelium Clinical and Applied Thrombosis/Hemostasis, January 1, 2002; 8(1): 65 - 71. [Abstract] [PDF]

				V. G. Nielsen, V. E. Armstead, B. T. Geary, and I. L. Opentanova PentaLyte(R) Does Not Decrease Heparinoid Release but Does Decrease Circulating Thrombotic Mediator Activity Associated with Aortic Occlusion-Reperfusion in Rabbits Anesth. Analg., February 1, 2001; 92(2): 314 - 319. [Abstract] [Full Text] [PDF]

				J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest, January 1, 2001; 119(1_suppl): 64S - 94S. [Full Text] [PDF]

				A. D. Westmuckett, C. Lupu, S. Roquefeuil, T. Krausz, V. V. Kakkar, and F. Lupu Fluid Flow Induces Upregulation of Synthesis and Release of Tissue Factor Pathway Inhibitor In Vitro Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20(11): 2474 - 2482. [Abstract] [Full Text] [PDF]

				J. Crawley, F. Lupu, A. D. Westmuckett, N. J. Severs, V. V. Kakkar, and C. Lupu Expression, Localization, and Activity of Tissue Factor Pathway Inhibitor in Normal and Atherosclerotic Human Vessels Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1362 - 1373. [Abstract] [Full Text] [PDF]

				H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]